source
- Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trialEli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…
- Merck’s eye-drug matches Lucentis in vision improvement but raises safety concernsMerck reported results from its Phase 2b/3 BRUNELLO trial of remigromig, a Wnt-pathway agonist for diabetic macular edema. The drug achieved non-inferior improvement in best-corrected visual acuit…